Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients
Table 2
Characteristics, demographics, and distribution of patients according to the induction and maintenance therapy received after transplantation.
Variables
Standard induction and maintenance therapy n = 159
Extended alemtuzumab exposure n = 179
value
Race (%)
0.42
Caucasians
157 (98.7)
173 (96.6)
Native Americans
1 (0.6)
4 (2.2)
African Americans
1 (0.6)
2 (1.1)
Age at transplant, years (mean ± SD)
43.03 ± 8.68
43.60 ± 8.76
0.54
Recipient gender, male (%)
86 (54.1)
87 (48.6)
0.37
Primary disease (%)
0.42
Diabetes type 1
151 (95.0)
164 (91.6)
Diabetes type 2
5 (3.1)
11 (6.1)
Native pancreatectomy
3 (1.9)
4 (2.2)
Transplant order (%)
0.59
PAK
70 (44.0)
76 (42.5)
PTA
42 (26.4)
56 (31.3)
SPK
47 (29.6)
47 (26.3)
Pancreatic duct drainagea
<0.0001
Bladder drainage
105 (67.3)
78 (44.8)
Enteric drainage
50 (32.1)
94 (54)
Other
1 (0.6)
2 (1.15)
Donors’ cause of death (%)
b0.40
Cardiovascular
1 (0.6)
2 (1.1)
Cerebrovascular
36 (22.6)
45 (25.1)
Trauma
67 (42.1)
120 (67.0)
Unknown
55 (34.6)
12 (6.7)
ECD (%)
1 (1.0)
3 (1.7)
1.00
DCD (%)
5 (3.2)
8 (4.5)
0.72
Total ischemic timec, minutes (mean ± SD)
1082.78 ± 306.36
1050.01 ± 281.92
0.33
History of transplant prior to 2002 (%)
34 (21.4)
34 (19.0)
0.68
Time to retransplant, days (mean ± SD)
1935.26 ± 1760.39
1944.76 ± 1310.70
0.98
Length of stayd, days (mean ± SD)
13.14 ± 14.83
14.41 ± 12.29
0.39
CMV serostatuse (%)
0.07
D+/R−f
32 (20.6)
57 (32.0)
R+
94 (60.6)
94 (52.8)
D−/R−
29 (18.7)
27 (15.2)
Gender D/R match (%)
91 (57.2)
90 (50.3)
0.24
aData available for 156/159 in the standard induction and maintenance therapy group, and 174/179 in the extended alemtuzumab exposure group. bChi-Square Test computed by omitting the unknowns. cTotal ischemic time is the summation of both cold and warm ischemic time. dLength of stay at the time of transplantation. eData are available for 155/159 for the standard induction and maintenance therapy group and 178/179 for the extended alemtuzumab exposure group. f. DCD: donation after cardiovascular death; D/R: donor/recipient; ECD: expanded criteria donors; PAK: pancreas after kidney transplant; PTA: pancreas transplant alone; SD: standard deviation; SPK: simultaneous pancreas and kidney transplant.
